Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016

  • ID: 3775418
  • Drug Pipelines
  • 69 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Amgen Inc.
  • AnGes MG, Inc.
  • Kringle Pharma, Inc.
  • M3 Biotechnology, Inc.
  • Molecular Partners AG
  • ViroMed Co., Ltd.
  • MORE
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016

Summary

‘Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016’, provides in depth analysis on Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted pipeline therapeutics.

The report provides comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)
- The report reviews Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Amgen Inc.
  • AnGes MG, Inc.
  • Kringle Pharma, Inc.
  • M3 Biotechnology, Inc.
  • Molecular Partners AG
  • ViroMed Co., Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Overview

Therapeutics Development

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Products under Development by Stage of Development

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Products under Development by Therapy Area

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Products under Development by Indication

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Products under Development by Companies

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Products under Development by Universities/Institutes

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Companies Involved in Therapeutics Development

Amgen Inc.

AnGes MG, Inc.

Kringle Pharma, Inc.

M3 Biotechnology, Inc.

Minerva Biotechnologies Corporation

Molecular Partners AG

ViroMed Co., Ltd.

Yooyoung Pharmaceutical Co., Ltd.

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Drug Profiles

beperminogene perplasmid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Antagonize HGF for Rheumatoid Arthritis and Hepatocellular Carcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MM-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-0250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rilotumumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-186 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YYB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Dormant Projects

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Discontinued Products

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Featured News & Press Releases

May 18, 2016: VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis

Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study

Jan 08, 2016: Molecular Partners to Conduct Phase II Trial of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Multiple Myeloma

Nov 07, 2015: Research Presented at AACR-NCI-EORTC Shows Good Tolerability and Sustained Systemic Exposure of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Patients with Advanced Cancer

Oct 27, 2015: First clinical data of multi-DARPin MP0250 to be presented at the AACR-NCI-EORTC oncology conference

Sep 01, 2015: US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer

Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia

Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition

Nov 24, 2014: Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer

Nov 13, 2014: First Patient Dosed in Global Phase III Clinical Trials of HGF Plasmid for Critical Limb Ischemia

Oct 29, 2014: AnGes to Start Global Phase III Clinical Trials of HGF Gene Therapy for Critical Limb Ischemia in Europe

Oct 16, 2014: First Patient Dosed in Physician-led Study of HGF Gene Therapy in Japan

Oct 05, 2014: AnGes Starts Global Phase III Clinical Trials of Collategene for Critical Limb Ischemia

Jun 16, 2014: Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer

Jun 12, 2014: AnGes Signs an Agreement with Quintiles for the Global Phase III Trial of Collategene, a Gene Therapy Product for Critical Limb Ischemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Amgen Inc., H1 2016

Pipeline by AnGes MG, Inc., H1 2016

Pipeline by Kringle Pharma, Inc., H1 2016

Pipeline by M3 Biotechnology, Inc., H1 2016

Pipeline by Minerva Biotechnologies Corporation, H1 2016

Pipeline by Molecular Partners AG, H1 2016

Pipeline by ViroMed Co., Ltd., H1 2016

Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Amgen Inc.
  • AnGes MG, Inc.
  • Kringle Pharma, Inc.
  • M3 Biotechnology, Inc.
  • Molecular Partners AG
  • ViroMed Co., Ltd.
  • MORE
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Hepatocyte Growth Factor – Pipeline Review, H1 2016, outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Amgen Inc.
AnGes MG, Inc.
Kringle Pharma, Inc.
M3 Biotechnology, Inc.
Minerva Biotechnologies Corporation
Molecular Partners AG
ViroMed Co., Ltd.
Yooyoung Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll